Localized tissue repair vs systemic repair vs antimicrobial defense — complete three-way comparison of mechanisms, stacking protocols, dosing guide, and decision tree for researchers.
BPC-157, TB-500, and LL-37 are three of the most commonly stacked research peptides in recovery and immune protocols — and for good reason. They cover three distinct biological systems with no known mechanism-based conflicts. BPC-157 is a localized tissue repair peptide, most potent at specific injury sites via EGR-1-mediated collagen synthesis and angiogenesis. TB-500 (Thymosin Beta-4) is a systemic repair peptide, promoting cell migration and tissue repair throughout the entire body via actin sequestration. LL-37 is a cathelicidin antimicrobial peptide, providing the innate immune defense layer — direct pathogen killing, anti-biofilm activity, and wound infection prevention.
BPC-157 handles the localized repair signal; TB-500 handles the systemic repair and anti-inflammatory response; LL-37 handles the antimicrobial barrier. In comprehensive recovery protocols, all three are often used simultaneously because they address different aspects of the healing process that do not overlap.
Research Disclaimer: All content on this page is for educational and research purposes only. These compounds are not FDA-approved for the indications discussed. Always consult a qualified healthcare professional before considering any peptide protocol.
Gastric Pentadecapeptide · 15 Amino Acids
Drives localized tissue repair via EGR-1 upregulation (collagen synthesis, angiogenesis) and NO-cGMP pathway activation (vasodilation, tissue perfusion). Most studied for tendon/ligament repair, gut healing (IBD, leaky gut), and musculoskeletal recovery.
Thymosin Beta-4 · 43-Amino Acid Systemic Repair Peptide
Drives systemic tissue repair via actin sequestration (G-actin binding promotes cell migration throughout the body). Strong anti-inflammatory effects via cytokine downregulation. Most studied for cardiac repair, systemic injury recovery, and neurological protection.
Cathelicidin · Human Antimicrobial Peptide · 37 Amino Acids
Provides innate immune defense via membrane disruption of bacteria and viruses, anti-biofilm activity against MRSA and Pseudomonas, and wound healing via keratinocyte migration and VEGF upregulation. Activates TLR4/FPRL1 for inflammatory modulation.
| Category | BPC-157 | TB-500 | LL-37 |
|---|---|---|---|
| Primary Mechanism | EGR-1 upregulation, NO-cGMP pathway, angiogenesis | Actin sequestration (G-actin binding), cell migration, anti-inflammatory | Membrane disruption, TLR4/FPRL1 signaling, keratinocyte migration |
| Repair Scope | Localized — most potent at specific injury sites | Systemic — body-wide tissue repair and cell migration | Wound-site — antimicrobial barrier and infection prevention |
| Wound Healing | Excellent — collagen synthesis, fibroblast activation | Excellent — cell migration, actin remodeling, angiogenesis | Significant — keratinocyte migration, anti-biofilm, infection prevention |
| Antimicrobial Activity | Minimal | Minimal | Excellent — direct membrane disruption; broad-spectrum |
| Anti-Inflammatory | Moderate — macrophage modulation | Strong — cytokine downregulation, systemic anti-inflammatory | Biphasic — pro-inflammatory acute; anti-inflammatory resolution |
| Gut Health | Excellent — gastric mucosal protection, IBD, leaky gut | Moderate — systemic anti-inflammatory benefits | Moderate — intestinal epithelial antimicrobial |
| Cardiac Repair | Moderate — studied in cardiac injury models | Strong — most studied peptide for cardiac repair | Minimal direct cardiac effects |
| Neurological Effects | Dopamine/serotonin modulation; TBI recovery | Studied for neurological protection and repair | Minimal direct neurological effects |
| Typical Dose | 250–500 mcg/day | 2–5 mg 2x/week | 100–500 mcg/day |
| Administration | SubQ injection (preferred) or oral | SubQ injection only | SubQ injection (preferred) or topical |
| Cycle Length | 4–12 weeks | 4–8 weeks | 4–8 weeks |
| Evidence Level | Extensive preclinical (rodent); limited human data | Extensive preclinical; Phase 2 cardiac trials | Extensive in vitro; growing in vivo; limited human trials |
Research Verdict
Three Distinct Systems — No Overlap, No Conflict
BPC-157, TB-500, and LL-37 are mechanistically non-overlapping: BPC-157 handles localized repair via EGR-1; TB-500 handles systemic repair via actin sequestration; LL-37 handles antimicrobial defense via membrane disruption. For comprehensive recovery protocols targeting tissue repair, systemic healing, and infection prevention simultaneously, this three-compound stack is among the most mechanistically complete combinations in peptide research.
The complete three-compound stack for comprehensive recovery research. BPC-157 drives localized tissue repair and gut healing; TB-500 provides systemic repair, cell migration, and anti-inflammatory effects throughout the body; LL-37 provides antimicrobial barrier function and wound infection prevention. This combination covers localized repair, systemic repair, and innate immune defense — three distinct biological systems with no known mechanism-based conflicts.
For research protocols targeting infected wound healing. LL-37 provides immediate antimicrobial defense and anti-biofilm activity at the wound site (can be applied topically). BPC-157 drives localized tissue repair and angiogenesis. TB-500 provides systemic anti-inflammatory effects and cell migration to support healing throughout the body.
For post-surgical recovery research protocols. TB-500 is particularly relevant for cardiac surgery recovery given its Phase 2 cardiac repair trial data. BPC-157 accelerates tissue repair at the surgical site and protects gut integrity. LL-37 provides antimicrobial protection against post-surgical infection. The combination covers the three main post-surgical recovery challenges: tissue repair, systemic healing, and infection prevention.
| Research Goal | Recommended | Rationale |
|---|---|---|
| Localized tendon / ligament repair | BPC-157 | Most potent for site-specific EGR-1-mediated collagen synthesis |
| Systemic / body-wide injury recovery | TB-500 | Actin sequestration promotes cell migration throughout the body |
| Gut healing (IBD, leaky gut, ulcers) | BPC-157 | Gastric mucosal protection; primary indication |
| Cardiac repair / recovery | TB-500 | Most studied peptide for cardiac repair; Phase 2 trial data |
| Antimicrobial / wound infection prevention | LL-37 | Direct membrane disruption; anti-biofilm activity |
| Systemic anti-inflammatory | TB-500 | Strongest anti-inflammatory cytokine modulation of the three |
| Neurological support (TBI, depression) | BPC-157 | Dopamine/serotonin modulation; studied in TBI models |
| Infected wound healing (complete) | Stack all three | BPC-157 (repair) + TB-500 (systemic) + LL-37 (antimicrobial) = comprehensive |
| Post-surgical recovery | Stack BPC-157 + TB-500 | Localized + systemic repair; add LL-37 if infection risk is present |
BPC-157 is a gastric pentadecapeptide that drives localized tissue repair via EGR-1 upregulation, angiogenesis, and NO-cGMP pathway activation — most studied for gut healing, tendon/ligament repair, and musculoskeletal recovery. TB-500 (Thymosin Beta-4) is a systemic actin-sequestering peptide that promotes cell migration and systemic tissue repair across the entire body. LL-37 is a cathelicidin antimicrobial peptide that provides innate immune defense — direct membrane disruption of bacteria and viruses, anti-biofilm activity, and wound infection prevention. Together they cover localized repair (BPC-157), systemic repair (TB-500), and antimicrobial defense (LL-37).
Yes — this three-compound stack is mechanistically rational and covers three distinct biological systems with no known interaction concerns. BPC-157 drives localized tissue repair and gut healing; TB-500 provides systemic tissue repair, cell migration, and anti-inflammatory effects; LL-37 provides antimicrobial barrier function and wound infection prevention. The combination is used in research protocols targeting comprehensive recovery with immune defense.
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43-amino acid peptide found in high concentrations in blood platelets and wound fluid. Its primary mechanism is actin sequestration — it binds G-actin monomers, which promotes cell migration, wound healing, and tissue repair throughout the body. TB-500 also has anti-inflammatory effects via downregulation of inflammatory cytokines, promotes angiogenesis, and has been studied for cardiac repair, neurological protection, and systemic injury recovery.
BPC-157 and TB-500 are complementary rather than competing. BPC-157 is more potent for localized tissue repair — it is the most studied peptide for tendon, ligament, gut, and musculoskeletal injuries, with direct EGR-1-mediated collagen synthesis. TB-500 provides broader systemic repair effects via actin sequestration and cell migration, and has stronger anti-inflammatory and cardiac repair data. For comprehensive injury recovery, stacking both is common in research protocols.
In recovery protocols, LL-37 serves as the antimicrobial defense layer — it prevents wound infection, disrupts biofilm formation at injury sites, and modulates the acute inflammatory response via TLR4/FPRL1 signaling. It is particularly relevant in protocols involving open wounds, post-surgical recovery, or research subjects with compromised innate immune function.
BPC-157 works primarily through EGR-1 upregulation (collagen synthesis, angiogenesis) and NO-cGMP pathway activation (vasodilation, tissue perfusion). TB-500 works primarily through actin sequestration (G-actin binding promotes cell migration and wound healing) and anti-inflammatory cytokine modulation. BPC-157 is more targeted to specific injury sites; TB-500 has more systemic, body-wide effects.
Use BPC-157 for localized tissue repair, gut healing, and musculoskeletal recovery. Use TB-500 for systemic repair, anti-inflammatory effects, cardiac recovery, and body-wide injury healing. Use LL-37 for antimicrobial defense, wound infection prevention, and innate immune support. For comprehensive recovery protocols, all three are often stacked as they cover complementary biological systems.
A common research protocol uses BPC-157 at 250–500 mcg/day SubQ, TB-500 at 2–5 mg 2x/week SubQ, and LL-37 at 100–200 mcg/day SubQ. Cycle lengths typically range from 4–12 weeks for BPC-157, 4–8 weeks for TB-500, and 4–8 weeks for LL-37. All three can be run simultaneously.
Purgo Labs carries pharmaceutical-grade BPC-157, TB-500, and LL-37 with third-party COA verification. Use code HEALTH for 15% off your order.
Visit Purgo LabsAffiliate disclosure: Compound Review may earn a commission on qualifying purchases.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.